TGFB1 and neoplasm: Additionally, Mariathasan et al. developed mouse models of EMT-6 and MC38 that mimicked the excluded tumor-immune phenotype and demonstrated that the combined use of TGF-β-blocking and anti-PD-L1 antibodies reduced TGF-β signaling in stromal cells.